UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Trip-killers: a concerning practice associated with psychedelic drug use
We recommend that emergency physicians ask patients about trip-killers if psychedelic drug use is suspected. This conversation should occur promptly on arrival to hospital, and before any benzodiazepines or antipsychotics are prescribed
Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy
The following reviews the current research for clinical pharmacotherapies, as well as MDMA-integrative psychotherapy as they pertain to PTSD and AUD in isolation and co-occurrence. Future directions for the role of psychedelic-integrative therapy for the treatment of this comorbidity are discussed.
Oral ketamine may offer a solution to the ketamine conundrum
Evidence suggests that low-dose oral ketamine is clinically effective in treating pain. This may also be due to the actions of norketamine and therefore, its relevance to the mental health context is explored in this narrative review.
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Seven days later, TNF-α concentrations returned to baseline, while IL-6 and CRP concentrations were persistently reduced in the psilocybin group ... Additionally, the more of a reduction in IL-6 and CRP seven days after psilocybin, the more persisting positive mood and social effects participants reported.
MAPS - conflict resolution, couples therapy, and more… exciting research projects in 2024
Proposed MAPS research projects for 2024 include MDMA-assisted Couples Therapy, Peace Building & Conflict Resolution, Marijuana for PTSD, and Psychedelics & the Legal System,
The relation between naturalistic use of psychedelics and perception of emotional stimuli: An event-related potential study comparing non-users and experienced users of classic psychedelics
The results suggest that naturalistic use of psychedelics may be linked to reduced reactivity to emotionally negative stimuli at the early and automatic processing stages.
Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder
Findings of the study showed safety (no treatment-related serious adverse events or suicidality) with psilocybin and suggested efficacy, with a significant reduction in depression severity scores from baseline to posttreatment. Further investigation is warranted.
Treatment with psychedelics is psychotherapy: beyond reductionism
Treatment of psychiatric disorders with psychedelic substances represents one of the most promising current treatment approaches in psychiatry.
MAPS PBC announces submission of new drug application to the FDA for MDMA-assisted therapy for PTSD
The FDA has 60 days to determine whether the NDA will be accepted for review and whether it will be a priority or standard review (six months or ten months, respectively).
Group psychedelic therapy: empirical estimates of cost-savings and improved access
Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies.
IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models
We suggest that classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments that are currently used in clinical settings, indicating broad compatibility of classic psychedelics with contemporary SUD treatment paradigms.
Greater subjective effects of a low dose of LSD in participants with depressed mood
These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.
Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: A nonrandomized controlled trial
The findings in this open-label nonrandomized controlled trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.
Tim Ferriss podcast with Dr Willoughby Britton — The hidden risks of meditation, overlaps with psychedelic risks, harm reduction strategies, how to choose a retreat, near-death experiences, and more
Tim Ferriss talks with Dr Willoughby Britton about her ground-breaking (and often unpopular) research highlighting potential dangers and worrying frequency of adverse effects associated with meditation practices (and similarly psychedelics).
